Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
SNN 
Smith & Nephew SNATS Inc (SNN)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/10/2025: SNN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 17.47% | Avg. Invested days 59 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 01/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.82B USD | Price to earnings Ratio 34.21 | 1Y Target Price 32.55 |
Price to earnings Ratio 34.21 | 1Y Target Price 32.55 | ||
Volume (30-day avg) 833653 | Beta 0.7 | 52 Weeks Range 23.42 - 31.42 | Updated Date 01/13/2025 |
52 Weeks Range 23.42 - 31.42 | Updated Date 01/13/2025 | ||
Dividends yield (FY) 3.13% | Basic EPS (TTM) 0.7 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.41% | Operating Margin (TTM) 11.6% |
Management Effectiveness
Return on Assets (TTM) 4.51% | Return on Equity (TTM) 5.84% |
Valuation
Trailing PE 34.21 | Forward PE 10.24 | Enterprise Value 13682272589 | Price to Sales(TTM) 1.92 |
Enterprise Value 13682272589 | Price to Sales(TTM) 1.92 | ||
Enterprise Value to Revenue 2.43 | Enterprise Value to EBITDA 13.78 | Shares Outstanding 435993984 | Shares Floating 820650693 |
Shares Outstanding 435993984 | Shares Floating 820650693 | ||
Percent Insiders 0.03 | Percent Institutions 7.58 |
AI Summary
Smith & Nephew SNATS Inc. Stock Overview:
Company Profile:
Detailed history and background:
- Founded in 1856 in the UK, originally a manufacturer of bandages and wound dressings.
- Expanded into medical devices in the 20th century, focusing on orthopedics, sports medicine, and wound management.
- Became a global leader in these areas, with over 16,000 employees worldwide.
Core Business Areas:
- Orthopaedics Reconstruction: Joint replacement implants, trauma fixation devices, bone cement, and surgical instruments.
- Sports Medicine & ENT: Arthroscopy instruments, sports medicine braces, and ear, nose, and throat devices.
- Advanced Wound Management: Dressings, negative pressure wound therapy, and skin substitutes.
Leadership and Corporate Structure:
- CEO: Deepak Nath
- Chairman: Dr. Andy Williams
- Diverse board of directors with expertise in healthcare and business.
- Decentralized operational structure with regional business units.
Top Products and Market Share:
- Top Products: JOURNEY II hip replacement system, GENESIS II knee system, PICO 7 Negative Pressure Wound Therapy System.
- Market Share: Global leader in joint replacement (14%), negative pressure wound therapy (25%), and advanced arthroscopy (20%).
- Performance and Reception: Products receive positive feedback for innovation and clinical outcomes.
Total Addressable Market:
- Global medical devices market: $450 billion (2022).
- Smith & Nephew's core markets: $250 billion.
Financial Performance:
- Revenue: $5.2 billion (2022)
- Net Income: $537 million (2022)
- Profit Margin: 10.3% (2022)
- EPS: $1.04 (2022)
- YoY Growth: Revenue +6.4%, EPS +12.5% (2022)
- Cash Flow: Strong cash flow with $637 million generated in 2022.
- Balance Sheet: Healthy balance sheet with low debt-to-equity ratio.
Dividends and Shareholder Returns:
- Dividend History: Consistent dividend payer, current yield 1.8%.
- Shareholder Returns: Total return of 15% over the past year, 50% over the past 5 years.
Growth Trajectory:
- Historical Growth: Revenue CAGR of 5% over the past 5 years.
- Future Growth: Projected to grow at 5-7% CAGR over the next 5 years, driven by aging population and rising healthcare spending.
- Recent Initiatives: Investments in digital surgery, robotics, and personalized medicine.
Market Dynamics:
- Industry Trends: Growing demand for minimally invasive procedures, personalized medicine, and robotics.
- Competitive Landscape: Intense competition from large and small players.
- Smith & Nephew's Positioning: Strong brand recognition, innovative products, and global presence.
Competitors:
- Main Competitors: Stryker (SYK), Medtronic (MDT), Johnson & Johnson (JNJ), Zimmer Biomet (ZBH).
- Market Share: Smith & Nephew holds a smaller market share compared to larger competitors.
- Competitive Advantages: Focus on innovation, strong R&D capabilities, and customer relationships.
Potential Challenges and Opportunities:
- Challenges: Supply chain disruptions, regulatory changes, and increasing competition.
- Opportunities: Emerging markets, digital health solutions, and new product launches.
Recent Acquisitions (last 3 years):
- 2021: Acquisition of Brainlab's digital surgery business for $1.3 billion.
- 2022: Acquisition of Ceterix Orthopaedics, Inc. for $265 million to expand foot and ankle portfolio.
- 2023: Acquired the remaining 70% stake in Ceterix for $65 million to solidify position in the foot and ankle segment.
- These acquisitions align with Smith & Nephew's strategy to invest in innovative technologies and expand into growing market segments.
AI-Based Fundamental Rating:
Rating: 8/10 Justification: Strong financials, leading market positions in core segments, consistent growth, and promising future outlook. Disclaimer: This rating is based on publicly available information and does not constitute financial advice.
Sources:
- Smith & Nephew's Investor Relations website.
- SEC filings.
- Market research reports from industry analysts.
** Disclaimer:** The information provided in this overview is for general knowledge and informational purposes only, and does not constitute investment advice. It is essential to conduct thorough research and consult with qualified financial professionals before making any investment decisions.
I hope this information is helpful! Please let me know if you have any other questions.
About NVIDIA Corporation
Exchange NYSE | Headquaters - | ||
IPO Launch date 1999-11-16 | CEO & Director Dr. Deepak S. Nath Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 18000 | Website https://www.smith-nephew.com |
Full time employees 18000 | Website https://www.smith-nephew.com | ||
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.